Cargando…

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pastick, Katelyn A, Okafor, Elizabeth C, Wang, Fan, Lofgren, Sarah M, Skipper, Caleb P, Nicol, Melanie R, Pullen, Matthew F, Rajasingham, Radha, McDonald, Emily G, Lee, Todd C, Schwartz, Ilan S, Kelly, Lauren E, Lother, Sylvain A, Mitjà, Oriol, Letang, Emili, Abassi, Mahsa, Boulware, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184359/
https://www.ncbi.nlm.nih.gov/pubmed/32363212
http://dx.doi.org/10.1093/ofid/ofaa130
_version_ 1783526592237010944
author Pastick, Katelyn A
Okafor, Elizabeth C
Wang, Fan
Lofgren, Sarah M
Skipper, Caleb P
Nicol, Melanie R
Pullen, Matthew F
Rajasingham, Radha
McDonald, Emily G
Lee, Todd C
Schwartz, Ilan S
Kelly, Lauren E
Lother, Sylvain A
Mitjà, Oriol
Letang, Emili
Abassi, Mahsa
Boulware, David R
author_facet Pastick, Katelyn A
Okafor, Elizabeth C
Wang, Fan
Lofgren, Sarah M
Skipper, Caleb P
Nicol, Melanie R
Pullen, Matthew F
Rajasingham, Radha
McDonald, Emily G
Lee, Todd C
Schwartz, Ilan S
Kelly, Lauren E
Lother, Sylvain A
Mitjà, Oriol
Letang, Emili
Abassi, Mahsa
Boulware, David R
author_sort Pastick, Katelyn A
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
format Online
Article
Text
id pubmed-7184359
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-71843592020-04-29 Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) Pastick, Katelyn A Okafor, Elizabeth C Wang, Fan Lofgren, Sarah M Skipper, Caleb P Nicol, Melanie R Pullen, Matthew F Rajasingham, Radha McDonald, Emily G Lee, Todd C Schwartz, Ilan S Kelly, Lauren E Lother, Sylvain A Mitjà, Oriol Letang, Emili Abassi, Mahsa Boulware, David R Open Forum Infect Dis Review Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines. Oxford University Press 2020-04-15 /pmc/articles/PMC7184359/ /pubmed/32363212 http://dx.doi.org/10.1093/ofid/ofaa130 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review Article
Pastick, Katelyn A
Okafor, Elizabeth C
Wang, Fan
Lofgren, Sarah M
Skipper, Caleb P
Nicol, Melanie R
Pullen, Matthew F
Rajasingham, Radha
McDonald, Emily G
Lee, Todd C
Schwartz, Ilan S
Kelly, Lauren E
Lother, Sylvain A
Mitjà, Oriol
Letang, Emili
Abassi, Mahsa
Boulware, David R
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
title Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
title_full Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
title_fullStr Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
title_full_unstemmed Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
title_short Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
title_sort review: hydroxychloroquine and chloroquine for treatment of sars-cov-2 (covid-19)
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184359/
https://www.ncbi.nlm.nih.gov/pubmed/32363212
http://dx.doi.org/10.1093/ofid/ofaa130
work_keys_str_mv AT pastickkatelyna reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT okaforelizabethc reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT wangfan reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT lofgrensarahm reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT skippercalebp reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT nicolmelanier reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT pullenmatthewf reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT rajasinghamradha reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT mcdonaldemilyg reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT leetoddc reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT schwartzilans reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT kellylaurene reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT lothersylvaina reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT mitjaoriol reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT letangemili reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT abassimahsa reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19
AT boulwaredavidr reviewhydroxychloroquineandchloroquinefortreatmentofsarscov2covid19